Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease

  • STATUS
    Recruiting
  • End date
    Dec 31, 2030
  • participants needed
    165
  • sponsor
    National Eye Institute (NEI)
Updated on 27 January 2021
Investigator
Daniel W Claus, R.N.
Primary Contact
Sydney Eye Hospital at the University of Sydney (0.9 mi away) Contact
+1 other location
eye exam
eye drops
other disease
electroretinogram

Summary

Background

The retina is a thin layer of tissue at the back of the eye. Retinal disease usually reduces a person s mobility because it affects how he or she moves through familiar and unfamiliar environments. Researchers want to see if a virtual reality (VR) tool can provide an easier and more accurate way to assess mobility.

Objective

To learn if researchers can track changes in mobility in people with retinal disease using a new VR tool.

Eligibility

People aged 5 and older with retinal disease that affects their vision, and healthy volunteers.

Design

Participants will have 1-2 clinic visits.

Participants will wear goggles while sitting. Using a game controller, they will navigate through 4 obstacle courses presented in VR.

Participants will have a medical history and physical exam. They will answer questions about their family history. They will fill out questionnaires about the vision and mobility issues they have in their daily lives.

Participants will have a complete eye exam. They will read letters from a chart. Their eye pressure will be measured. Their pupils may be dilated with eye drops. Pictures of their eye will be taken. Lights will be shined in their eyes.

Participants will take a visual field test. For this, they will look into a dome and press a button when they see a light.

Participants will have an electroretinogram. For this, they will sit in the dark with their eyes patched. Then their eyes will be numbed with eye drops and they will wear contact lenses while watching flashing lights.

Participants will have optical coherence tomography. This is a noninvasive procedure. It produces cross-sectional pictures of the retina....

Description

Objective: Designing clinical trials for advanced retinal disease represents an especially difficult challenge due to the lack of suitable outcome measures. Clinical measures such as visual field and area of atrophy measured with multimodal imaging may be highly variable and/or difficult to measure in this population. A main contributor to disability in the visually impaired is poor mobility, which is a quality of life measure used to assess visually-guided behavior in low-vision patients. The goal of our study is to determine whether parameters from a recently developed virtual reality (VR) mobility assessment tool may serve as biomarkers of functional vision in participants with advanced retinal disease. The long-term goal will be to determine whether the VR mobility assessment tool parameters can document longitudinal changes in functional vision and serve as a suitable outcome measure for clinical trials in participants with advanced retinal disease.

Study Population: Up to 120 participants with retinal disease and 45 healthy volunteers will be recruited. The upper limit of 120 participants with retinal disease was chosen to allow approximately equal groups of 60 participants with rod-cone degeneration (RCD) and 60 participants with cone-rod degeneration (CRD) to represent groups of participants with peripheral visual field constriction and central vision loss, respectively. A total of 60 per group was chosen to A) allow feasibility to be determined across age groups (e.g., 5-11 yrs., 12-50 years, over 50 years) and B) to allow for a sufficient range of disease severity to examine VR mobility test sensitivity. The number of healthy volunteers (N=45) was chosen to provide about 15 participants across each of three age groups.

Design: In this multi-site observational study, VR mobility testing will be performed in participants with retinal disease. While the ultimate goal is to use this for advanced retinal disease, in the current study we will examine patients with a wide range of retinal disease severity to enable correlations between VR mobility parameters and markers of disease severity (e.g. field size, mobility scores from questionnaires). This analysis will also help determine the range of retinal disease severity for which VR mobility will be useful. Testing will also include best corrected visual acuity (BCVA), visual fields, optical coherence tomography (OCT), autofluorescence imaging, ultra-widefield imaging and participant reported outcome (PRO) questionnaires. Based on the simulation studies, we predict that participants should be able to repeat the VR course between four to eight times in a one-hour session. Participants will be required to attend up to two clinic visits within three months. VR testing will be the focus of the second clinic visit in order to A) examine the learning effect and B) quantify test-retest variability of VR test parameters.

Outcome Measures: The primary outcome is to determine whether parameters from a recently developed VR mobility tool can serve as biomarkers of functional vision in participants with retinal disease. To this end, we will examine the correlation between VR mobility test parameters (e.g., accuracy, task time) and clinical measures of retinal structure and function (e.g., visual acuity, non-seeing area) and the mobility score from a PRO questionnaire/s. Other primary outcomes include quantifying the learning effect and test-retest variability of the VR test parameters. A secondary outcome is to examine whether prior or present computer game playing (e.g., number of hours, type of games played, computer game platform) influences baseline performance on the VR mobility tool.

Details
Condition Retinitis Pigmentosa, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration, Rod-Cone Degeneration
Treatment VR Motility Tool
Clinical Study IdentifierNCT04289571
SponsorNational Eye Institute (NEI)
Last Modified on27 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

To be eligible, the following inclusion criteria must be met
Participant must be five years of age or older
Participant (or legal guardian) must understand and sign the protocol's informed consent document
Participant must be able to cooperate with the testing required for this study
For participants with retinal disease only
Participant must have retinal disease, defined as retinal dysfunction and/or degeneration as established by standard clinical methods including perimetry, ERG and imaging
For healthy volunteers only
Participant must not have a retinal disease and have visual acuity of 20/20 or better, with or without correction (e.g., glasses or contact lens) in at least one eye

Exclusion Criteria

A participant is not eligible if any of the following exclusion criteria are
present
Participant is in another investigational study and actively receiving study therapy
Participant is unable to comply with study procedures
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note